Mount Sinai Study Validates DiA’s Cardiac Ultrasound AI Finding it Comparable to Cardiac MRI

The study results demonstrate accuracy of AI-based ultrasound software, enabling a quicker detection of dysfunction caused by COVID-19, Pulmonary Embolism, and more


DiA Imaging Analysis, the leading provider of advanced AI-based software for ultrasound analysis, was featured in a recent study presented by a team of cardiac physicians from Mount Sinai’s Icahn School of Medicine to the American Heart Association. The breakthrough study demonstrated the accuracy of LVivo RV, the company's AI for Right Ventricle Function (RVF) analysis, validating its sensitivity and specificity results in comparison to Cardiac MRI (CMR).


Right Ventricle size and function are key indicators of cardiac dysfunction, including pulmonary embolism (PE), pulmonary hypertension, as well as right heart failure. In the midst of the Covid-19 pandemic, cardiac ultrasound imaging should include assessment of the RV to detect RV dysfunction, commonly seen in patients with COVID-19. Although common, RVF analysis using an ultrasound device is challenging and often requires additional examination, due to the RV’s challenging geometry.


The recent study of 125 patients compared DiA’s right heart AI-based software to CMRI. Results demonstrated a high sensitivity and specificity when compared to CMR, the gold standard of cardiac imaging. The study concluded that DiA’s automated AI-based right heart analysis for fully automated RVF quantification has the potential to accurately and instantly detect evidence of right heart dysfunction at the bedside.


Said Dr. Martin Goldman, a cardiovascular disease specialist at Mount Sinai and one of the authors of the study, “As echo is the first imaging triage modality used for scanning suspected heart issues, this study validated the potential of adding AI as part of our cardiac ultrasound workflow”

“We are proud to share that leading physicians from the Icahn School of Medicine at Mount Sinai, a globally ranked program, have validated our FDA-approved AI platform,” said Hila Goldman-Aslan, CEO and co-founder of DiA Imaging Analysis. “The LVivo RV provides an automated solution to the critical analysis of RVF, enabling the gold standard to be available to all cardiology patients.”


The study, Validation of Artificial Intelligence for Assessing Right Ventricular Function by Transthoracic Echocardiography, was conducted by Brian Hsia, Ashton Lai, Rajeev Samtani, Solomon Bienstock, Steve Liao, Eric Stern, Gina LaRocca, Javier Sanz, Stamatios Lerakis, Gregg W Stone, Lori Croft, and Martin Goldman, of the Icahn School of Medicine at Mount Sinai, New York, NY. The results were presented to the American Heart Association on November 15, 2021. The study was published at Circulation Magazine, Volume 144, Issue 1.


DiA will demonstrate its suite of AI-based ultrasound software solutions at RSNA 2021 in Chicago, IL. Nov 28th - Dec 2nd.


70 views0 comments